Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT05581823 Completed - Parkinson Disease Clinical Trials

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Start date: October 19, 2022
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.

NCT ID: NCT05579379 Not yet recruiting - Parkinson Disease Clinical Trials

DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD

Start date: October 2022
Phase:
Study type: Observational

20 patients with idiopathic Parkinson's disease, who are planned to undergo intestinal L-Dopa + entacapone (Lecigon®) treatment will be included into this observational single-armed study. These patient will be observed for hyperdopaminergic complications and neuropsychiatric fluctuations postprocedure at 3, 6 and 12 months.

NCT ID: NCT05576818 Recruiting - Parkinson Disease Clinical Trials

Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease

Start date: June 30, 2022
Phase: Phase 3
Study type: Interventional

This study aims to investigate the possible efficacy and safety of synbiotic preparation of Lactobacillus acidophilus probiotic with prebiotic fibers as an adjuvant therapy in the treatment of Parkinson's disease

NCT ID: NCT05575479 Completed - Parkinson Disease Clinical Trials

PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables

PDQ
Start date: August 2015
Phase:
Study type: Observational

The primary aim of the study will be to examine Social Cognitive Theory (SCT) correlates, of physical activity (PA) participation and health-related quality of life (HRQoL) in Parkinson's disease participants.

NCT ID: NCT05573542 Enrolling by invitation - Parkinson Disease Clinical Trials

Early Signs of Parkinsons Disease in IBS

Start date: May 1, 2023
Phase:
Study type: Observational

Bowel symptoms like constipation and abdominal pain are characteristic symptoms of irritable bowel syndrome (IBS). The pathogenesis and pathophysiology are not fully understood but subject to intense research, with emphasis on aberrations in the gut-brain axis, low-grade inflammation and gut barrier dysfunction that results in increased permeability and microbial translocation. Many patients with Parkinson's disease (PD) have reported bowel symptoms similar to that in IBS patients decades prior to the diagnosis of PD. Epidemiological studies show a significantly elevated risk of developing PD in IBS patients, though there is no knowledge on a pathogenic connection between these disorders. Recent studies show increased gut permeability and intestinal presence of pathological alpha-synuclein aggregates, the neuropathological hallmark in PD, indicating the involvement of the gut-brain axis. We aim to compare the presence of colonic alpha-synuclein between IBS, PD patients and healthy controls to relate these findings to intestinal permeability, ultrastructural mucosal changes, immune cell interactions, microbiota composition and brain function. This project could identify IBS groups at risk of developing PD and birth the development of early clinical diagnostic methods.

NCT ID: NCT05568498 Not yet recruiting - Depression Clinical Trials

Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

ProD
Start date: October 30, 2022
Phase: Phase 2
Study type: Interventional

This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either 12-week multi-strain probiotic treatment or placebo with an optional fMRI scan.

NCT ID: NCT05568199 Recruiting - Clinical trials for Deep Brain Stimulation

Udall Project 1 Aim 4

Start date: March 5, 2024
Phase:
Study type: Observational

By defining the strength and direction of connectivity patterns at rest and during movement across the basal ganglia-thalamocortical (BGTC) network we will characterize the role of individual circuits in motor performance and cognitive function, paving the way for future development of optimization algorithms for DBS that take advantage of this understanding.

NCT ID: NCT05565443 Recruiting - Parkinsons Disease Clinical Trials

MR-guided Focused Ultrasound Plus GCase

Start date: November 30, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.

NCT ID: NCT05565300 Completed - Parkinson Disease Clinical Trials

Effects of Cycling Dual-task in Parkinson's Disease.

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

Taking into account the process of functional and cognitive evolution that patients with Parkinson's disease experience throughout the evolution of the pathology, the objective of this study is to evaluate the effect of a dual-task program combining cognitive tasks and forced cycling on the functional and cognitive capacity of these patients.

NCT ID: NCT05561348 Recruiting - Parkinson Disease Clinical Trials

The Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Impairments in PD

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on Parkinson's disease patients . We hypothesize that treatment using transcutaneous auricular vagus nerve stimulation will improve gait impairments and cortical activity in Parkinson's disease patients.